SCHEMBL1900227

SCHEMBL1900227

Cc1ccc2nc(-c3cccs3)cc(C(=O)Nc3nnc(-c4ccco4)o3)c2c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 5/20 0.81
LMNA P02545 7/20 0.63
KDM4E B2RXH2 7/20 0.63
ALDH1A1 P00352 5/20 0.63
HPGD P15428 4/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
KMT2A Q03164 3/20 0.63
HTT P42858 3/20 0.63
MAPT P10636 3/20 0.63
GLA P06280 3/20 0.63
MEN1 O00255 2/20 0.63
TDP1 Q9NUW8 2/20 0.63
HCRTR1 O43613 1/20 0.63
MAPK1 P28482 1/20 0.63
ADCY8 P40145 1/20 0.58
ADCY1 Q08828 1/20 0.58
RAB9A P51151 3/20 0.53
ALOX12 P18054 3/20 0.53
NPC1 O15118 2/20 0.53
RXFP1 Q9HBX9 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1897496 0.90 STAT3 (0.81) STAT3LMNAKDM4EALDH1A1HPGD
SCHEMBL1900732 0.90 STAT3 (1.00) STAT3LMNAKDM4EALDH1A1HPGD
SCHEMBL1897309 0.87 STAT3 (0.72) STAT3LMNAKDM4EALDH1A1HPGD
SCHEMBL1897448 0.87 STAT3 (0.81) STAT3LMNAKDM4EALDH1A1HPGD
SCHEMBL1898262 0.85 STAT3 (0.75) STAT3LMNAKDM4EALDH1A1HPGD
SCHEMBL1897499 0.82 STAT3 (0.77) STAT3LMNAKDM4EALDH1A1HPGD
SCHEMBL1902149 0.81 STAT3 (0.63) STAT3LMNAKDM4EALDH1A1HPGD
SCHEMBL1900839 0.81 STAT3 (0.75) STAT3LMNAKDM4EALDH1A1HPGD
SCHEMBL1904403 0.81 STAT3 (0.82) STAT3LMNAKDM4EALDH1A1HPGD
SCHEMBL1898648 0.80 STAT3 (0.87) STAT3LMNAKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B STAT3 1/4885LMNA 4766/4885KDM4E 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.